** Amgen AMGN.O shares little changed at $288.82 ahead of Q4 earnings due after the closing bell
** The biotech company is expected to post EPS of $5.08 per share, compared with $4.71 a year ago, on revenue of $8.88 bln, per LSEG data, vs yr-ago results of and $8.2 bln in revenue
** AMGN has met or beat EPS expectations in 6 of past 8 qtrs, with most recent miss in Q2 2024
** Of the 33 analysts that cover Amgen Inc, the breakdown of recommendations are 16 "strong buy" or "buy," 14 "hold" and 3 "sell" or "strong sell" ratings
** Median price target of $316 is down from $331.50 a month ago
** AMGN shares up 10.7% YTD vs 4.8% gain in Dow Industrials .DJI
** AMGN options imply a 4.4% swing for the shares, in either direction, by Fri, in line with the stock's 8-qtr avg 1-day move after results, according to according to Trade Alert
(Reporting by Chuck Mikolajczak, additional reporting by Saqib Ahmed)
((charles.mikolajczak@tr.com; @ChuckMik;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。